Valneva Plunges 37% After Lyme Vaccine Fails Phase 3 Trial; Law Firm Launches Investigation

Pomerantz LLP has initiated a securities fraud investigation into Valneva SE ($VALN) and its partner Pfizer ($PFE) following a catastrophic clinical trial failure that erased over one-third of the vaccine developer's market value in a single trading session. The collapse of the Phase 3 Lyme disease vaccine candidate, known as LB6V, represents a significant setback for the long-anticipated therapeutic addressing a major public health gap, and has triggered intense scrutiny from investor protection advocates and securities law experts.

The stock price collapse—a devastating 37.11% decline on March 23, 2026—marks one of the steepest single-day losses for the company and underscores the enormous financial stakes riding on clinical trial outcomes in the vaccine and biopharmaceutical sector. The investigation comes as investors seek answers about whether key stakeholders adequately disclosed risks or made misleading statements regarding the likelihood of the vaccine's success.

The Failed Trial and Market Reaction

Valneva's LB6V represented a potentially transformative asset in the company's pipeline. Lyme disease, transmitted through infected tick bites, affects tens of thousands of Americans annually and generates significant healthcare costs. A safe and effective vaccine would have addressed a critical unmet medical need, particularly given the geographic prevalence of Lyme disease in parts of North America and Europe.

The failure to meet the primary endpoint in Phase 3 testing represented a watershed moment:

• 37.11% stock price decline on the announcement date
• Elimination of a potentially blockbuster asset from the pipeline
• Questions raised about trial design, patient population selection, and efficacy metrics
• Significant impact on the joint development and commercialization partnership with Pfizer

The speed and magnitude of the market reaction reflects investor confidence evaporating almost instantly following the announcement. In biotech and vaccine development, Phase 3 failure represents the most expensive and public form of clinical disappointment—billions in development costs effectively wiped out with no regulatory pathway forward.

Market Context and Competitive Landscape

The failure of LB6V arrives amid renewed interest in Lyme disease vaccines. The original LYMErix vaccine was withdrawn from the market in 2002 following public safety concerns and litigation, leaving a decades-long vacuum in vaccine availability. Valneva's partnership with Pfizer was designed to capitalize on renewed demand and greater scientific understanding of the disease.

The broader immunization market context matters significantly:

• Lyme disease incidence continues rising in endemic regions due to climate patterns and tick population changes
• Growing patient advocacy for vaccine solutions following years without approved options
• Competitive landscape includes other companies pursuing Lyme vaccines with varying clinical progress
• Regulatory pathway expected to be well-established following LYMErix precedent, potentially making approval faster if efficacy demonstrated

Valneva's dependence on this asset was substantial. As a smaller biopharmaceutical company, the company's pipeline concentration meant that LB6V represented a significant portion of near-term revenue potential and valuation rationale. Pfizer's involvement provided credibility and resources, but also meant reputational impact for the larger partner.

The investigation by Pomerantz LLP focuses on whether executives made statements regarding trial probability of success that were inconsistent with internal data or undisclosed risk factors. Securities litigation following failed clinical trials often hinges on whether companies adequately warned investors about potential downside scenarios or made affirmative misstatements about efficacy metrics.

Investor Implications and Shareholder Impact

For $VALN shareholders, the implications extend well beyond the single-day stock decline:

• Cash burn implications: Without LB6V revenue, burn rate becomes more critical to assess going forward
• Pipeline sustainability: Investors must evaluate whether Valneva possesses other viable assets or partnership opportunities
• Pfizer partnership dynamics: Questions about continued collaboration, potential exit, or reallocation of resources
• Litigation risk premium: Legal liability exposure could significantly impact financial position
• Regulatory credibility: Potential scrutiny of future trial designs and data interpretation

The securities investigation adds litigation risk that could extend monetary damages well beyond the stock price impact. Institutional shareholders and pension funds holding $VALN may pursue legal claims independently or through class-action vehicles. Settlement costs, legal fees, and potential disgorgement of compensation to executives could materially impact the company's balance sheet.

For the broader vaccine and immunization sector, the failure underscores the binary nature of clinical development—years and billions in spending can culminate in a failed trial, instantly destroying shareholder value. This reality influences how investors evaluate biotech companies with concentrated pipelines. Diversification of assets and advanced-stage clinical programs become critical valuation factors.

Pfizer's involvement provides some buffering effect given the company's diversified portfolio, but the partnership failure still represents a setback. Pharma companies typically absorb development costs and write off impaired assets—public partners like Valneva, however, often lack the balance sheet cushion to absorb such losses without material financial consequences.

Forward-Looking Considerations

The investigation by Pomerantz LLP will likely focus on securities filings, earnings call transcripts, and internal communications spanning the period before the Phase 3 failure announcement. Investors should monitor:

• Settlement announcements that could provide clarity on financial exposure
• Updated guidance from Valneva on cash runway and strategic alternatives
• Pipeline updates announcing acceleration of other programs or partnership developments
• Executive leadership changes that sometimes follow major clinical setbacks

The LB6V failure demonstrates that even well-capitalized partnerships with major pharma companies cannot guarantee clinical success. For investors in smaller biopharmaceutical firms, this serves as a reminder that concentrated pipelines carry existential risk—a single failed trial can fundamentally alter investment thesis and shareholder returns.